Synthetic approaches to the 2013 new drugs

被引：66
作者：
Ding, Hong X. [1 ]
Leverett, Carolyn A. [4 ]
Kyne, Robert E., Jr. [4 ]
Liu, Kevin K. -C. [2 ]
Fink, Sarah J. [3 ]
Flick, Andrew C. [4 ]
O'Donnell, Christopher J. [4 ]
机构：
[1] Pharmacodia Beijing Co Ltd, Beijing 100085, Peoples R China
[2] Lilly China Res & Dev Ctr, Shanghai 201203, Peoples R China
[3] BioDuro Co Ltd, Shanghai 200131, Peoples R China
[4] Pfizer Worldwide Res & Dev, Groton Labs, Groton, CT 06340 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY | 2015年 / 23卷 / 09期
关键词：
Synthesis; New drug molecules; New chemical entities; Medicine; Therapeutic agents; ADENOSINE RECEPTOR ANTAGONISTS; PALLADIUM-CATALYZED SYNTHESIS; PARKINSONS-DISEASE; DOUBLE-BLIND; ENANTIOSELECTIVE SYNTHESIS; ASYMMETRIC-SYNTHESIS; SELECTIVE INHIBITOR; DISCOVERY; 1ST; MACITENTAN;
D O I：
10.1016/j.bmc.2015.02.056
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：1895 / 1922
页数：28
相关论文
共 223 条
[41]   Synthetic approaches to the 2012 new drugs [J].
Ding, Hong X. ;
Leverett, Carolyn A. ;
Kyne, Robert E., Jr. ;
Liu, Kevin K. -C. ;
Sakya, Subas M. ;
Flick, Andrew C. ;
O'Donnell, Christopher J. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (07) :2005-2032
[42]   Synthetic approaches to the 2011 new drugs [J].
Ding, Hong X. ;
Liu, Kevin K. -C. ;
Sakya, Subas M. ;
Flick, Andrew C. ;
O'Donnell, Christopher J. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (11) :2795-2825
[43]   Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension [J].
Dingemanse, Jasper ;
Sidharta, Patricia N. ;
Maddrey, Willis C. ;
Rubin, Lewis J. ;
Mickail, Hani .
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (03) :391-405
[44]  
Dowdy E., 2008, WO Patent, Patent No. [2008033836, 2008033836A2]
[45]  
Dowdy E., 2009, WO Patent, Patent No. [2009036161A1, 2009036161]
[46]  
Doyle MP, 2001, ADV SYNTH CATAL, V343, P299, DOI 10.1002/1615-4169(20010330)343:3<299::AID-ADSC299>3.3.CO
[47]  
2-P
[48]  
Duan M., 2010, Patent, Patent No. [WO2010068262A1, 2010068262, 2010068262A1]
[49]   Afatinib: First Global Approval [J].
Dungo, Rosselle T. ;
Keating, Gillian M. .
DRUGS, 2013, 73 (13) :1503-1515
[50]  
Ebens Jr A. J., 2005, WO Patent, Patent No. [2005117986A2, 2005117986]
12345678910